What We're Reading: Page 87
Industry reads hand-picked by our editors
Mar 02, 2023
-
Fierce Biotech
Alzheimer’s meds are here, but not for Down syndrome patients
-
Financial Times
Anorexia is the deadliest psychiatric disorder. Could psychedelics help?
-
Endpoints News
A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can’t make enough of it
-
Reuters
Genentech sues Biogen for royalties on blockbuster MS drug
Mar 01, 2023
-
CNN
Covid vaccine maker Novavax says it may not survive
-
The Wall Street Journal
Congress Investigates How Pharma Middlemen Affect Drug Prices
-
Healthcare Dive
Why regulators didn’t challenge Amazon-One Medical deal, despite data concerns
-
Associated Press
How officials cracked case of eyedrops that blinded people
Feb 28, 2023
Feb 27, 2023
Feb 24, 2023
-
The New York Times
After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique
-
Reuters
First Zantac cancer risk trial in California postponed by months
-
Evaluate Vantage
US deal watchdog’s bark could be worse than its bite
-
Nature
Data hint at Russia’s shifting science collaborations after year of war
Feb 23, 2023
-
Reuters
Senator Warren urges U.S. patent office to scrutinize Merck’s Keytruda
-
Fierce Biotech
AbbVie pays $70M to expand Capsida collab into eye disease
-
The Wall Street Journal
Wall Street Backs New Class of Psychedelic Drugs
Feb 22, 2023
-
The Boston Globe
‘We can’t take our foot off the gas now’: MassBio’s new CEO takes the reins.
-
Science
Case studies expose deadly risk of mpox to people with untreated HIV
-
Financial Times
AbbVie accused of overcharging Dutch for flagship drug Humira
-
FirstWord Pharma
Alnylam’s effort to expand Onpattro use to go before FDA panel
Previous
